Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Gain Therapeutics

Request full access

Preclinical stage biotech company developing a class of next generation brain-penetrant non-competitive pharmacological chaperones for the treatment of devastating diseases using the proprietary…

Lugano, SwitzerlandFounded 2017Biotech & Life Sciences

About Gain Therapeutics

Gain Therapeutics is a biotechnology company focused on developing innovative small molecule therapeutics for disorders with high unmet medical needs. Utilizing a combination of physics-based methods and artificial intelligence, Gain Therapeutics creates next-generation allosteric small molecules that can modulate proteins to restore or disrupt their function. These molecules can inhibit, activate, stabilize, destabilize, or degrade proteins based on the specific disease pathology. The company primarily serves the healthcare and pharmaceutical sectors, targeting conditions that currently lack effective treatments. Gain Therapeutics operates in the global biotechnology market and follows a business-to-business (B2B) model, partnering with other pharmaceutical companies for clinical development and commercialization. Revenue is generated through licensing agreements, milestone payments, and royalties from successful drug candidates.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2021
Employees
25
Open positions
None listed
Dealroom signal
61.8/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Drug Development, Biotech and Pharma, Hard Tech, Horizon Europe, proteomics, DT and LS, science-based, Swiss DT Biotech
Business model
Manufacturing
Client focus
B2B

Funding history

9 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
POST IPO EQUITY✓Other financing Jul 2025 $7M — Undisclosed ↗
POST IPO EQUITY✓Other financing Jun 2024 $11M — Undisclosed ↗
Showing the latest 2 of 9 recorded eventsBook a demo for the full funding history →

Growth signals

Gain Therapeutics website traffic

Latest recorded traffic for Gain Therapeutics is 21K monthly website visits, up 75% over the last three months. Gain Therapeutics's team declined 19.4% over the past year.

Latest monthly visits21K 3-month web change+75% 1-year team growth-19.4%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Gain Therapeutics in the Lugano ecosystem

Live from Dealroom

The Gain Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Innosuisse

Series A2 investors entered at this stage

  • 3B Future Health Fund
  • TiVentures

Series B and later1 investor entered at this stage

  • Minoryx Therapeutics

Other known investors1 additional known investor

  • Emerging Technology Partners Biomedical
Team profiled 9 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Gain Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.